Compare D Wave Quantum Inc (QBTS) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? D Wave Quantum Inc trades at $14.55 (market cap $5.54B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 10.6× D Wave Quantum Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| QBTS | TAK | |
|---|---|---|
Market Cap | $5.54B | $58.74B |
Volume | 16,671,452 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $44.78 | $19.05 |
52-Week Low | $12.98 | $13.23 |
Typical Hold Time | 32 Days | 1 Days |
Enterprise Value | $5.04B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum (QBTS) trades at $14.57, down 4.27% today, amid ongoing legal investigations and negative earnings trends. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal severe losses with a -2,001.59% net income margin despite 64.19% gross margins. Recent quarterly earnings have been mixed, missing expectations in two of the last three reported quarters.
Despite unanimous analyst buy ratings and a $34.38 price target suggesting 136% upside, significant execution risks persist. The company faces cash burn challenges with negative operating cash flow and relies heavily on financing activities. Legal investigations and competitive pressures in the quantum computing sector create substantial uncertainty for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
